ADVERTISEMENT

Consumer group urges PCC probe on pneumonia vaccines

Published Mar 28, 2022 10:59 am

Former Congressman, Jonathan dela Cruz, National advisor of the advocacy group United Filipino Consumers and Commuters (UPCC), talked about government losses in an alleged monopoly in pneumonia vaccine procurement during the Kapihan ng Samahang Plaridel.

According to dela Cruz, the government is losing billions of pesos because of a near-marketplace dominance in the procurement of pneumococcal vaccines (PCVs), the largest vaccine tender in the world. PCVs are meant to prevent child pneumonia, one of the top killer diseases among children five-years old and below. Based on a UNICEF study, one child dies every 39 seconds because of pneumonia.

United Filipino Consumers and Commuters (UFCC) national consultant and former ABAKADA partylist Congressman, Jonathan Dela Cruz, revealed in the recent Kapihan ng Samahang Plaridel forum that the government has been overcharged billions of pesos by a single pharmaceutical company in the procurement of this vaccine. Because of this, UFCC filed a complaint before the Philippine Competition Commission (PCC) to investigate the alleged anti-competition practice.

In yesterday's Kapihan, dela Cruz said that the government might be unknowingly losing billions in procuring unnecessarily expensive pneumonia vaccines. As an example, he pointed out that U.S. biopharmaceutical company, Pfizer, did not have credible competition for the PCVs, but started to offer P816 per single dose to capture the market. Then, to increase their chances of winning the recent bids, "kung saan mayroong nagbabantang bagong kompetisyon, binaba nila ang presyo hanggang makaabot ng P345 per dose. So, ninanakawan mo na ang gobyerno, niyari mo pa mga kabataan na dapat nabigyan ng mga bakuna. (When they faced new competitors in the last bidding, they brought down the price of their vaccine to P345 per dose. So, they did not only steal from the government, but they also compromised our ability to inoculate more of our children if the price were lower in the first place).”

dela Cruz said that he suspects what seems to be a monopoly is happening as both Pfizer and Zuellig Pharma are offering and pushing the same PCV13 vaccine, locking out other potential players.

dela Cruz further questioned the effects of this suspected pneumonia vaccine monopoly, citing recent studies of the World Health Organization (WHO) declaring that there are three available PCV vaccines that are comparable and not inferior to each other.

Since 2014, the Philippines, through its childhood immunization program, has been using the more expensive PCV13 from Pfizer, despite WHO studies that showed that PCV10 is "non-inferior" or at parity with the PCV13 vaccines.

In 2020, there were calls to open up the PCV tender to other players, which up to that point was being dominated by Pfizer. The government, through the Department of Health (DOH), responded and opened the PCV bidding to other pharmaceutical corporations.

dela Cruz said that when the bidding was re-opened and a new competitor for the PCV was considered, Pfizer again suddenly reduced its price from P5.5-billion annually to just P2.6-billion in the new bidding. As other players came in, they continually lowered their price for the bidding.

"Ninanakawan ang ating gobyerno ng walang kalaban-laban dahil sa supposed monopoly na ito (The government is being robbed helplessly because of this supposed monopoly), " dela Cruz said.

Aside from the alleged monopoly, dela Cruz also revealed other harmful dynamics from other players that occur during the biddings:  "’Yung mga ibang big pharma ay kunwaring magka- kompetisyon, ngunit sa totoo lang ay mag-sweetheart o magka-kuntsaba (The other big pharmas pretend to be competing against each other, but the truth is they are ‘sweethearts’ or accomplices.)  They collude and help steer the bidding of other pharma manufacturers so they can stay and dominate the procurement process.”

The Kapihan discussion also revealed that the other pharma, Zuellig Pharma, has started to acquire companies beyond the pharmaceutical sector, such as manufacturing and logistics, to try to corner the market. dela Cruz believes this tactic will further hold the government hostage in choosing them as the preferred PCV suppliers in the national formulary, while preventing the formation of a level-playing field that can give Filipinos more affordable choices when it comes to vaccines.

The UFCC’s complaint before the PCC asked the independent anti-monopoly regulatory body to issue a cease-and-desist order and to temporarily suspend the procurement of PCVs while the investigation is still ongoing.

Pera ng bayan ang kanilang kinakamkam dito, na naapektuhan ang mga bata.” (This is the country’s money they are stealing from, and that theft is affecting our children.)

Related Tags

Samahang Plaridel vaccine
ADVERTISEMENT
.most-popular .layout-ratio{ padding-bottom: 79.13%; } @media (min-width: 768px) and (max-width: 1024px) { .widget-title { font-size: 15px !important; } }

{{ articles_filter_1561_widget.title }}

.most-popular .layout-ratio{ padding-bottom: 79.13%; } @media (min-width: 768px) and (max-width: 1024px) { .widget-title { font-size: 15px !important; } }

{{ articles_filter_1562_widget.title }}

.most-popular .layout-ratio{ padding-bottom: 79.13%; } @media (min-width: 768px) and (max-width: 1024px) { .widget-title { font-size: 15px !important; } }

{{ articles_filter_1563_widget.title }}

{{ articles_filter_1564_widget.title }}

.mb-article-details { position: relative; } .mb-article-details .article-body-preview, .mb-article-details .article-body-summary{ font-size: 17px; line-height: 30px; font-family: "Libre Caslon Text", serif; color: #000; } .mb-article-details .article-body-preview iframe , .mb-article-details .article-body-summary iframe{ width: 100%; margin: auto; } .read-more-background { background: linear-gradient(180deg, color(display-p3 1.000 1.000 1.000 / 0) 13.75%, color(display-p3 1.000 1.000 1.000 / 0.8) 30.79%, color(display-p3 1.000 1.000 1.000) 72.5%); position: absolute; height: 200px; width: 100%; bottom: 0; display: flex; justify-content: center; align-items: center; padding: 0; } .read-more-background a{ color: #000; } .read-more-btn { padding: 17px 45px; font-family: Inter; font-weight: 700; font-size: 18px; line-height: 16px; text-align: center; vertical-align: middle; border: 1px solid black; background-color: white; } .hidden { display: none; }
function initializeAllSwipers() { // Get all hidden inputs with cms_article_id document.querySelectorAll('[id^="cms_article_id_"]').forEach(function (input) { const cmsArticleId = input.value; const articleSelector = '#article-' + cmsArticleId + ' .body_images'; const swiperElement = document.querySelector(articleSelector); if (swiperElement && !swiperElement.classList.contains('swiper-initialized')) { new Swiper(articleSelector, { loop: true, pagination: false, navigation: { nextEl: '#article-' + cmsArticleId + ' .swiper-button-next', prevEl: '#article-' + cmsArticleId + ' .swiper-button-prev', }, }); } }); } setTimeout(initializeAllSwipers, 3000); const intersectionObserver = new IntersectionObserver( (entries) => { entries.forEach((entry) => { if (entry.isIntersecting) { const newUrl = entry.target.getAttribute("data-url"); if (newUrl) { history.pushState(null, null, newUrl); let article = entry.target; // Extract metadata const author = article.querySelector('.author-section').textContent.replace('By', '').trim(); const section = article.querySelector('.section-info ').textContent.replace(' ', ' '); const title = article.querySelector('.article-title h1').textContent; // Parse URL for Chartbeat path format const parsedUrl = new URL(newUrl, window.location.origin); const cleanUrl = parsedUrl.host + parsedUrl.pathname; // Update Chartbeat configuration if (typeof window._sf_async_config !== 'undefined') { window._sf_async_config.path = cleanUrl; window._sf_async_config.sections = section; window._sf_async_config.authors = author; } // Track virtual page view with Chartbeat if (typeof pSUPERFLY !== 'undefined' && typeof pSUPERFLY.virtualPage === 'function') { try { pSUPERFLY.virtualPage({ path: cleanUrl, title: title, sections: section, authors: author }); } catch (error) { console.error('ping error', error); } } // Optional: Update document title if (title && title !== document.title) { document.title = title; } } } }); }, { threshold: 0.1 } ); function showArticleBody(button) { const article = button.closest("article"); const summary = article.querySelector(".article-body-summary"); const body = article.querySelector(".article-body-preview"); const readMoreSection = article.querySelector(".read-more-background"); // Hide summary and read-more section summary.style.display = "none"; readMoreSection.style.display = "none"; // Show the full article body body.classList.remove("hidden"); } document.addEventListener("DOMContentLoaded", () => { let loadCount = 0; // Track how many times articles are loaded const offset = [1, 2, 3, 4, 5, 6, 7, 8, 9, 10]; // Offset values const currentUrl = window.location.pathname.substring(1); let isLoading = false; // Prevent multiple calls if (!currentUrl) { console.log("Current URL is invalid."); return; } const sentinel = document.getElementById("load-more-sentinel"); if (!sentinel) { console.log("Sentinel element not found."); return; } function isSentinelVisible() { const rect = sentinel.getBoundingClientRect(); return ( rect.top < window.innerHeight && rect.bottom >= 0 ); } function onScroll() { if (isLoading) return; if (isSentinelVisible()) { if (loadCount >= offset.length) { console.log("Maximum load attempts reached."); window.removeEventListener("scroll", onScroll); return; } isLoading = true; const currentOffset = offset[loadCount]; window.loadMoreItems().then(() => { let article = document.querySelector('#widget_1690 > div:nth-last-of-type(2) article'); intersectionObserver.observe(article) loadCount++; }).catch(error => { console.error("Error loading more items:", error); }).finally(() => { isLoading = false; }); } } window.addEventListener("scroll", onScroll); });

Sign up by email to receive news.